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Objective: The aim of this multicenter prospective study was to evaluate the efﬁcacy of a new
bioequivalent formulation of oseltamivir for the treatment of inﬂuenza A, inﬂuenza B, and H1N1 during
the 2010–2011 inﬂuenza season.
Methods: We compared the symptoms and signs of 300 pediatric patients presenting to three university
hospitals with an inﬂuenza-like illness between January and March 2011. Nasal swab specimens were
collected from all children and tested by reverse-transcription polymerase chain reaction (RT-PCR) for
inﬂuenza viruses. After randomization, half of the participants were prescribed oseltamivir, while the
other half were observed conservatively. Forty patients who were followed-up for inﬂuenza prior to the
study were also included in the evaluation.
Results: Inﬂuenza was conﬁrmed by RT-PCR in 129 children, 71 of whom were prescribed oseltamivir.
The durations of the symptoms fever, cough, nasal congestion, and rhinorrhea were signiﬁcantly shorter
for patients who were treated with oseltamivir compared with untreated patients (p < 0.002 for all
symptoms). Early initiation of oseltamivir therapy (within 48 h of the onset of symptoms) was associated
with more favorable outcomes and an earlier recovery than in patients for whom treatment was delayed
(beyond 48 h). Thirty-seven patients (28.7%) had H1N1, 44 (34.1%) had inﬂuenza A, 46 (35.7%) had
inﬂuenza B, one (0.8%) had H1N1 plus inﬂuenza A, and one (0.8%) had inﬂuenza A plus inﬂuenza B
viruses. In the comparison of the duration of symptoms according to the different virus types, a
statistically signiﬁcant difference was only observed in patients with inﬂuenza B who had a longer
duration of cough (p < 0.001), nasal congestion (p < 0.001), and rhinorrhea (p < 0.001).
Conclusions: Oseltamivir is an effective treatment for the management of seasonal inﬂuenza and H1N1,
and should be initiated immediately without waiting for laboratory conﬁrmation of diagnosis.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Inﬂuenza is a major threat worldwide, resulting in severe illness
and deaths each year, and is caused by the circulation of inﬂuenza
viruses that are ubiquitous in the population. Each year, during the
inﬂuenza season, the viruses spread rapidly, with 5–20% of the
population reported to be infected by inﬂuenza viruses. In the USA
alone, an estimated annual average of 36 000 deaths and 1 200 000* Corresponding author. Tel.: +90 312 3051166; fax: +90 312 3108241.
E-mail address: dredakaradag@gmail.com (E. Karadag Oncel).
1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.12.008hospitalizations are attributable to inﬂuenza virus infections,1,2
with similar rates reported in Europe and Asia.3,4
Infections with seasonal viruses tend to be more severe and
progress more rapidly in young infants, the elderly, and those
with an immunodeﬁciency, cardiopulmonary disease, pregnan-
cy, or other chronic illnesses.5,6 These patient groups are
considered to be at high risk for inﬂuenza-associated complica-
tions, which include sinusitis, otitis media, croup, bronchitis,
and pneumonia.2
Antiviral drugs used in the treatment of seasonal inﬂuenza
accelerate the decline in viral load, shorten the duration of viral
shedding, and reduce the length of hospital stay,7 while also
decreasing the risk of death.8,9 The US Centers for Disease Controlses. Published by Elsevier Ltd. All rights reserved.
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aminidase inhibitors such as oseltamivir and zanamivir (rather
than amantadine or rimantadine) for the treatment of seasonal
inﬂuenza in individuals presenting to medical care with symptoms
of less than 48-h duration.1 Oseltamivir has been the most widely
used drug in clinical practice, with more than 65 million
prescriptions worldwide.
Potential inﬂuenza cases can be identiﬁed based on clinical
signs and symptoms suggestive of inﬂuenza, without the need for
laboratory conﬁrmation. These inﬂuenza-like symptoms have
been shown to be more speciﬁc when making a diagnosis of
inﬂuenza during an epidemic.10
Seasonal inﬂuenza is associated with signiﬁcant morbidity and
mortality in the pediatric population, as well as placing a heavy
burden on health costs due to substantial use of hospital
resources.11–13 School-age children are an important source for
the spread of the inﬂuenza virus, with reported attack rates of
more than 40% in preschool children and 30% in school children
during inﬂuenza epidemics. The socioeconomic impact of
pediatric inﬂuenza on children and other household members
is substantial.14,15
In this study, a group of children who presented with
inﬂuenza-like symptoms were treated with oseltamivir, and
comparisons were made with patients who were treated
conservatively in terms of duration of symptoms as well as
efﬁcacy of and response to treatment. Oseltamivir has been used
in capsule form (Tamiﬂu1) and as an oral suspension (Tamiﬂu1)
in Turkey for several years. Since Tamiﬂu has been the only
oseltamivir preparation in our country and its use increased
during the recent inﬂuenza pandemic, there have been problems
in the supply of this drug. Oseltamivir has been made available
and licensed for the therapy and prevention of pediatric
inﬂuenza in Turkey as an oral suspension under the name
Enﬂuvir1. This study was planned to determine the effective-
ness of this new formulation in pediatric patients with
inﬂuenza. In addition, the presence and subtypes of inﬂuenza
viruses encountered in the 2010–2011 inﬂuenza season were
determined, and differences in clinical presentations were
investigated.
2. Methods
2.1. Study population and design
This prospective multicenter study of patients presenting to the
pediatric outpatient clinics and the emergency departments of
three university hospitals in Turkey, namely Hacettepe University,
C¸ukurova University, and Ege University, was undertaken between
January and March 2011.
Children aged 18 years presenting with inﬂuenza-like illness
during the study period were enrolled in the study after parental
consent was obtained. A broad deﬁnition of acute respiratory
illness was used to identify patients who had potentially
contracted inﬂuenza: the presence of two or more signs or
symptoms (temperature 37.8 8C, cough, headache, sore throat,
myalgia, congestion, and rhinorrhea) with a duration of one or
more days during follow-up, as deﬁned in previous studies.16 The
surveillance deﬁnition for inﬂuenza-like illness recommended by
the CDC (temperature 37.8 8C plus cough or sore throat) was also
used.17 An inﬂuenza surveillance questionnaire was completed for
each patient to obtain information on patient age, inﬂuenza
vaccination status, beginning and end of symptoms, presence of
complications, use of medications (antipyretics, antibiotics, anti-
virals, etc.), need for hospitalization, and the presence of an
underlying chronic disorder.2.2. Laboratory tests
Nasal swab specimens were collected from all children who
presented with inﬂuenza-like symptoms. The specimen was
obtained from a depth of 2–3 cm using a sterile cotton swab
inserted into the nostril and was then inoculated into a vial
containing M4 viral transport medium (Medical Wire & Equip-
ment, UK). Swabs were stored at room temperature and
transported to the Virology Laboratory of Istanbul University to
be tested for seasonal inﬂuenza viruses by reverse-transcription
polymerase chain reaction (RT-PCR) within 72 h of collection. The
standard operating protocol as deﬁned by the CDC was adhered to
throughout this process.
After nasal swabs were obtained, patients were randomized
and assigned to either the oseltamivir treatment group or the
untreated group. Doses were set based on CDC recommendations.
For children less than 1 year of age, oseltamivir was given at a dose
of 3 mg/kg twice daily. Older children were prescribed the drug at
doses adjusted to their weight: 15 kg, 30 mg twice a day; 15–
23 kg, 45 mg twice a day; 24–40 kg, 60 mg twice a day; >40 kg,
75 mg twice a day.
A standard protocol was followed at all three centers, which
required participants to attend follow-up visits on the third, ﬁfth,
and tenth day of treatment, with the aim of ensuring patient
compliance and to monitor side effects and the duration of
symptoms. Patients/parents were asked to measure body temper-
ature at least three times a day. A patient was considered afebrile
when his/her body temperature remained <37.5 8C for more than
24 h without the use of antipyretics. The highest body temperature
during the course of the disease was also recorded. Time to
resolution of symptoms that were present on ﬁrst presentation
(e.g., cough, sore throat, myalgia, congestion and rhinorrhea,
vomiting, and diarrhea) was also noted. For patients who could not
be brought to the hospital, parents were contacted by phone.
The study was approved by the institutional review boards at
the University of Hacettepe. Informed consent was obtained from
the parent or legal guardian of each participant, and participants
aged 6 years completed assent procedures.
2.3. Statistical analysis
Statistical analyses were performed using Stata version 15.0
(Stata Corp., College Station, TX, USA) and the R statistical package
(version 2.10.1). Comparisons of proportions between the groups
were done by the standard Chi-square test and Fisher’s exact test.
The Mann–Whitney U-test and Kruskal–Wallis one-way analysis
of variance according to rank were used to compare nonparametric
continuous data between the groups. The bivariate Spearman
correlation test was used to examine the strength of association
between the starting time of oseltamivir and duration of
symptoms. A p-value of less than 0.05 was considered to be
indicative of statistical signiﬁcance.
3. Results
3.1. Demographic characteristics
During the period from January through March 2011, a total of
300 patients with inﬂuenza-like illness were evaluated. The
median age of patients was 36 months (interquartile range 2–
204 months) and 55% were male. Of the 300 patients, none had a
chronic disorder such as asthma, or a chronic pulmonary or cardiac
disease. Forty-ﬁve of the three-hundred patients (15%) included in
the study had been vaccinated with the seasonal inﬂuenza vaccine
before presenting to our hospital.
Table 1
Comparison of the duration of symptoms between RT-PCR positive and negative
patients presenting with inﬂuenza-like symptoms
Parameter RT-PCR-positive
(n)a
RT-PCR-negative
(n)a
p-Value
Fever 4.56  2.56
(126)
3.88  1.60
(129)
0.024
Cough 6.79  3.51
(112)
6.08  3.13
(136)
0.056
Nasal congestion 5.61  3.21
(113)
5.41  2.81
(141)
0.418
Rhinorrhea 5.53  3.16
(115)
5.53  2.81
(130)
0.983
Sore throat 3.15  1.18
(40)
3.51  1.36
(56)
0.618
Myalgia 5.50  2.33
(31)
3.74  2.01
(16)
0.02
Headache 4.54  3.26
(30)
3.83  2.40
(33)
0.518
Breathing difﬁculties 2.57  1.39
(7)
2.36  1.43
(11)
0.696
a Results are mean  standard deviation days (number of patients with the
symptom).
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The most common symptoms on ﬁrst presentation were fever
(262/300, 87.3%), cough (254/300, 84.7%), nasal congestion (259/
300, 86.3%), rhinorrhea (251/300, 83.7%), sore throat (96/300, 32%),
headache (64/300, 21.3%), and myalgia (49/300, 16.3%). Only 8.7%
(26/300) of patients reported gastrointestinal tract symptoms such
as nausea, vomiting, or diarrhea. Lower respiratory tract ﬁndings
were respiratory distress in 18.6%, crepitations in 5.3%, and
wheezing in 3.1%. Physical ﬁndings on presentation were
consistent with acute otitis media in seven patients (2.3%), acute
bronchiolitis in three patients (1%), and acute sinusitis in one
patient (0.3%). Neurological symptoms (febrile convulsion, en-
cephalopathy, etc.) were present in four patients (1.3%) at
presentation.Figure 1. Study assignmWith regard to drug use before presentation, 275 patients
(91.7%) had used antipyretics, while 103 patients (34.3%) reported
antibiotic use. The most commonly used antipyretic was paracet-
amol (82%), and amoxicillin–clavulanic acid was the most
frequently used antibiotic (78%). Thirteen patients (4.3%) were
hospitalized due to breathing difﬁculties, feeding problems, and
deterioration of general condition, although none of them required
observation in the intensive care unit.
At least one inﬂuenza virus was detected in 129 (43%) patients
using the RT-PCR method. One hundred and sixty-four (54.7%)
samples were negative and seven (2.3%) swabs were deemed
inadequate.
When RT-PCR positive and negative patients were compared in
terms of duration of symptoms, RT-PCR-positive patients had
signiﬁcantly longer periods of fever (p < 0.05) and myalgia
(p < 0.05). Although the duration of cough was longer in the RT-
PCR-positive group, the difference was not statistically signiﬁcant
(p = 0.056) (Table 1).
3.3. Treatment and clinical course
After randomization, half of the participants were prescribed
oseltamivir, while the other half were observed conservatively.
Findings were compared with those of 40 patients who were
followed-up for inﬂuenza prior to the study. Oseltamivir was
prescribed for 129 (43%) patients, while 171 (57%) patients
remained untreated with an antiviral agent. Figure 1 depicts the
study assignment and follow-up. The durations of fever, cough,
nasal congestion, and rhinorrhea from onset were signiﬁcantly
shorter in seasonal inﬂuenza patients who were treated with
oseltamivir than in those who were not treated (for all four
symptoms, p < 0.002). The frequency and duration of symptoms in
both groups are summarized in Table 2.
In the treated group, 55 patients (43.7%) had a positive RT-PCR
compared to 71 patients (56.3%) who were RT-PCR-negative. Of the
129 patients with a conﬁrmed inﬂuenza infection, 71 (55.0%) wereent and follow-up.
Table 2
Duration of symptoms in oseltamivir treated and untreated RT-PCR-positive
inﬂuenza patients
Parameter Oseltamivir treated (n)a Untreated (n)a p-Value
Fever 3.76  2.27
(69)
5.52  2.59
(57)
0.000
Cough 6.28  3.78
(63)
7.44  3.04
(49)
0.002
Nasal congestion 5.16  3.39
(62)
6.17  1.26
(51)
0.001
Rhinorrhea 5.01  3.16
(68)
6.27  3.04
(47)
0.001
Sore throat 2.98  1.21
(22)
3.01  1.28
(18)
0.678
Myalgia 3.72  2.16
(18)
3.76  1.87
(13)
0.665
Headache 3.95  2.83
(20)
3.60  1.26
(10)
0.734
a Results are mean  standard deviation days (number of patients with the
symptom).
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severe adverse reactions were reported in association with the
drug.
The effect of oseltamivir on the duration of symptoms was
evaluated based on the duration between the onset of symptoms
and initiation of the treatment. Duration of symptoms such as fever
(p < 0.001, R = 0.373), cough (p < 0.001, R = 0.470), nasal conges-
tion (p < 0.001, R = 0.348), and rhinorrhea (p < 0.001, R = 0.401)
were signiﬁcantly longer in patients for whom treatment was
delayed (>48 h). The use of an antibiotic prior to oseltamivir
treatment did not have a statistically signiﬁcant effect on the
duration of symptoms.
With regard to the distribution of inﬂuenza virus types/
subtypes in patients with a positive RT-PCR, 37 patients (28.7%)
had H1N1, 44 (34.1%) had inﬂuenza A, 46 (35.7%) had inﬂuenza B,
one (0.8%) had H1N1 plus inﬂuenza A, and one (0.8%) had inﬂuenza
A plus inﬂuenza B. In terms of duration of symptoms, a statistically
signiﬁcant difference was only observed in patients with inﬂuenza
B who had a longer duration of cough (p < 0.001), nasal congestion
(p < 0.001), and rhinorrhea (p < 0.001). Figure 2 depicts the
frequency of symptoms according to type/subtype of inﬂuenza
virus.
Among the 45 patients who had previously been vaccinated
with the seasonal inﬂuenza vaccine, 33 (73.3%) had a negative RT-Figure 2. Frequency of symptoms accordiPCR result, ﬁve (11.1%) had conﬁrmed inﬂuenza A, ﬁve (11.1%) had
inﬂuenza B, and two were positive for H1N1.
Of the patients who presented with acute otitis media, three
were positive for H1N1, two were positive for inﬂuenza B, and one
was positive for inﬂuenza A. Only one patient had a negative RT-
PCR result. The only patient with acute sinusitis had H1N1. Out of
the three patients with febrile convulsions, one had H1N1, one had
inﬂuenza B, while one patient had a negative RT-PCR result. The
patient who developed encephalopathy had inﬂuenza B.
Gastrointestinal symptoms were present in 18 (14%) patients
who were inﬂuenza-positive; seven had inﬂuenza A, six had
inﬂuenza B, and ﬁve had H1N1.
RT-PCR was positive in ﬁve of the 13 patients who were
hospitalized, three of whom had inﬂuenza B and two had H1N1.
The hospitalization rate was not signiﬁcantly different between
the RT-PCR positive and negative groups. The overall hospitali-
zation rate for patients with a conﬁrmed inﬂuenza infection was
3.8%. Tachypnea and breathing difﬁculties were the indications
for hospitalization in three patients, whereas one patient was
admitted due to feeding problems as a result of nausea and
vomiting. One patient was hospitalized after developing
encephalopathy.
4. Discussion
Early administration of oral oseltamivir has been reported to be
associated with earlier resolution of symptoms in patients with
inﬂuenza. Several large prospective studies in pediatric and adult
patients have clearly shown that antiviral therapy reduces the
duration of symptomatic illness by up to 2 days if started within
48 h of the onset of symptoms.18,19 In one trial, children aged 1–12
years with inﬂuenza-like illness of <48 h duration received either
oseltamivir or placebo twice daily for 5 days.20 Compared with
placebo, oseltamivir signiﬁcantly reduced symptom duration in
those with laboratory-conﬁrmed inﬂuenza (n = 452) by 36 h
(p < 0.0001), while also decreasing the extent and severity of
illness by 29% (p = 0.002). In our study on children with conﬁrmed
inﬂuenza, a new syrup formulation of oseltamivir therapy resulted
in a signiﬁcant reduction in the mean time to resolution of fever
from 5.52 days to 3.76 days (p = 0.000), cough from 7.44 days to
6.28 days (p = 0.002), nasal congestion from 6.17 days to 5.16 days
(p = 0.001), and rhinorrhea from 6.27 days to 5.01 days (p = 0.001).ng to type/subtype of inﬂuenza virus.
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in patients with a suspected inﬂuenza infection, without waiting
for laboratory conﬁrmation of the diagnosis,21 citing that the
earlier these drugs are started, the better the clinical outcome.18
The replication of inﬂuenza viruses peaks at 24–72 h after the
onset of symptoms, and the viral load correlates positively with the
severity of symptoms.18,22,23 Based on our knowledge, early
administration of oseltamivir would be expected to provide the
greatest clinical beneﬁt. This is also supported by our study results.
Fever was clearly the most prominent sign of inﬂuenza, as has
been reported previously by other investigators.24 However, a
recent meta-analysis revealed that fever occurred in only one-third
of healthy participants who were exposed to an experimental
seasonal inﬂuenza virus infection.25 Only 2.3% of children in the
inﬂuenza-positive group were afebrile in our study. In uncompli-
cated seasonal inﬂuenza, illness typically resolves within 3–7
days.1 In our inﬂuenza-positive patient group, symptoms resolved
after 1.5–8 days, with oseltamivir treatment associated with a
mean duration of fever of 1.7 days.
Treatment with oseltamivir also resulted in signiﬁcant reduc-
tions in the duration of cough,26 with an observed mean duration
of reduction of 1.2 days. Similar reductions in the durations of nasal
congestion (1 day) and rhinorrhea (1.2 days) were also observed.
When we look at the clinical severity and complications, we see
that gastrointestinal symptoms were documented in only 14.0% of
the RT-PCR-positive children in our study. However, they have
been reported to occur in approximately one-third of children with
inﬂuenza.27,28 In our study, 4.7% of RT-PCR-positive children had
acute otitis media at their ﬁrst visit, a rate much lower than those
reported in previous studies.29,30
Neurological dysfunction is an important complication of
inﬂuenza infections,31 with reported cases of encephalopathy,32
febrile seizure,33 Reye’s syndrome,34 and encephalitis lethargica.35
Febrile seizure is by far the most common neurological complica-
tion, with reported rates of more than 20% in children hospitalized
for inﬂuenza.34 The neurological complication rate in our RT-PCR-
positive study population was 2.3% and most of them were febrile
seizures.
Treatment with oseltamivir has been shown to decrease the use
of antibiotics in children with inﬂuenza by 10% (p = 0.03).26,36
However, we could not demonstrate similar reductions in our
study population. This may be related to the low rate of
complications in our patients. Our hospitalization rate was 3.9%
in patients with conﬁrmed inﬂuenza, all of whom were younger
than 5 years of age with a mean age of 34 months. Hospitalization
rates in the USA were highest in this age group according to a
summary report published by the CDC on inﬂuenza activity
covering the period between October 3, 2010 and February 5,
2011.37
In our study, patients infected with inﬂuenza B had signiﬁcantly
longer durations of the symptoms cough, nasal congestion, and
rhinorrhea, compared to those positive for inﬂuenza A (H1N1 and
unspeciﬁed subtypes). In comparison to seasonal inﬂuenza,
pandemic H1N1 has been shown to be associated with a
signiﬁcantly higher rate of symptoms in children presenting with
ﬂu-like symptoms (p < 0.05).38 A recent study also demonstrated a
weaker response to oseltamivir therapy in patients infected with
inﬂuenza B compared to inﬂuenza A, with the inﬂuenza B virus
being isolated more frequently than the inﬂuenza A virus following
treatment with oseltamivir.
In conclusion, oseltamivir therapy is associated with signiﬁcant
reductions in the duration of symptoms, and should be considered
in all patients thought to be at high risk for developing severe
complications. We strongly recommend early initiation of antiviral
therapy without waiting for laboratory conﬁrmation of the
diagnosis.Conﬂict of interest: None.
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